167 related articles for article (PubMed ID: 15857146)
81. Radiosynthesis of a ⁶⁸Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging.
Claesener M; Schober O; Wagner S; Kopka K
Appl Radiat Isot; 2012 Aug; 70(8):1723-8. PubMed ID: 22750564
[TBL] [Abstract][Full Text] [Related]
82. PAC-1 and isatin derivatives are weak matrix metalloproteinase inhibitors.
Sjøli S; Solli AI; Akselsen O; Jiang Y; Berg E; Hansen TV; Sylte I; Winberg JO
Biochim Biophys Acta; 2014 Oct; 1840(10):3162-9. PubMed ID: 25046380
[TBL] [Abstract][Full Text] [Related]
83. MMP inhibition by barbiturate homodimers.
Wang J; Radomski MW; Medina C; Gilmer JF
Bioorg Med Chem Lett; 2013 Jan; 23(2):444-7. PubMed ID: 23246356
[TBL] [Abstract][Full Text] [Related]
84. Imaging probes targeting matrix metalloproteinases.
Van de Wiele C; Oltenfreiter R
Cancer Biother Radiopharm; 2006 Oct; 21(5):409-17. PubMed ID: 17105415
[TBL] [Abstract][Full Text] [Related]
85. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.
Fei X; Zheng QH; Liu X; Wang JQ; Sun HB; Mock BH; Stone KL; Miller KD; Sledge GW; Hutchins GD
Bioorg Med Chem Lett; 2003 Jul; 13(13):2217-22. PubMed ID: 12798337
[TBL] [Abstract][Full Text] [Related]
86. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.
Hugenberg V; Hermann S; Galla F; Schäfers M; Wünsch B; Kolb HC; Szardenings K; Lebedev A; Walsh JC; Mocharla VP; Gangadharmath UB; Kopka K; Wagner S
Nucl Med Biol; 2016 Jul; 43(7):424-37. PubMed ID: 27179748
[TBL] [Abstract][Full Text] [Related]
87. Quest for selectivity in inhibition of matrix metalloproteinases.
Brown S; Meroueh SO; Fridman R; Mobashery S
Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
[TBL] [Abstract][Full Text] [Related]
88. Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases.
Breyholz HJ; Kopka K; Schäfers M; Wagner S
Pharmaceuticals (Basel); 2017 May; 10(2):. PubMed ID: 28556793
[TBL] [Abstract][Full Text] [Related]
89. [Development of Novel Nuclear Medical Imaging Probes for Quantification of Matrix Metalloproteinases in Diseases].
Kondo N
Yakugaku Zasshi; 2020; 140(1):7-13. PubMed ID: 31902888
[TBL] [Abstract][Full Text] [Related]
90. Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography.
Butsch V; Börgel F; Galla F; Schwegmann K; Hermann S; Schäfers M; Riemann B; Wünsch B; Wagner S
J Med Chem; 2018 May; 61(9):4115-4134. PubMed ID: 29660282
[TBL] [Abstract][Full Text] [Related]
91. Synthesis and evaluation of novel oxazoline MMP inhibitors.
Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
[TBL] [Abstract][Full Text] [Related]
92. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
Yan YL; Miller MT; Cao Y; Cohen SM
Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
[TBL] [Abstract][Full Text] [Related]
93. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents.
Oltenfreiter R; Staelens L; Lejeune A; Dumont F; Frankenne F; Foidart JM; Slegers G
Nucl Med Biol; 2004 May; 31(4):459-68. PubMed ID: 15093816
[TBL] [Abstract][Full Text] [Related]
94. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
Scozzafava A; Supuran CT
Bioorg Med Chem Lett; 2002 Oct; 12(19):2667-72. PubMed ID: 12217351
[TBL] [Abstract][Full Text] [Related]
95. The next generation of MMP inhibitors. Design and synthesis.
De B; Natchus MG; Cheng M; Pikul S; Almstead NG; Taiwo YO; Snider CE; Chen L; Barnett B; Gu F; Dowty M
Ann N Y Acad Sci; 1999 Jun; 878():40-60. PubMed ID: 10415719
[TBL] [Abstract][Full Text] [Related]
96. Zinc-binding groups modulate selective inhibition of MMPs.
Agrawal A; Romero-Perez D; Jacobsen JA; Villarreal FJ; Cohen SM
ChemMedChem; 2008 May; 3(5):812-20. PubMed ID: 18181119
[TBL] [Abstract][Full Text] [Related]
97. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
[TBL] [Abstract][Full Text] [Related]
98. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.
Dormán G; Cseh S; Hajdú I; Barna L; Kónya D; Kupai K; Kovács L; Ferdinandy P
Drugs; 2010 May; 70(8):949-64. PubMed ID: 20481653
[TBL] [Abstract][Full Text] [Related]
99. Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents.
Oltenfreiter R; Staelens L; Kersemans V; Cornelissen B; Frankenne F; Foidart JM; Van de Wiele C; Slegers G
Appl Radiat Isot; 2006 Jun; 64(6):677-85. PubMed ID: 16546398
[TBL] [Abstract][Full Text] [Related]
100. Making a new turn in matrix metalloprotease inhibition.
Wasserman ZR
Chem Biol; 2005 Feb; 12(2):143-4. PubMed ID: 15734640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
